Khoo Shih is Chief Executive Officer of ClavystBio, where she previously served as Senior Investment Advisor and part of the founding team. She brings more than 25 years of experience investing across global life sciences and healthcare companies in both private and public markets.
Prior to ClavystBio, Khoo Shih spent 17 years at Temasek in roles of increasing responsibility across Life Science Investments, including serving as Managing Director. Earlier in her career, she was an Investment Manager at UOB Venture Management. She began her career in Biomedical Sciences at the Singapore Economic Development Board and was part of the team that spearheaded the growth of the biomedical industry in Singapore.
She currently serves on the Board of Directors of Cirrus Therapeutics, Nuevocor and Paratus Sciences, and the Supervisory Board of Leyden Labs.
Khoo Shih holds a B.S. in microbiology from the National University of Singapore, and a Ph.D. in genetics and development from the University of Texas Southwestern Medical Center.
